For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

NCCN and PCWG Recommend mCRPC Patients Be Monitored Closely for Progression1,2

  • NCCN recommends using PSA tests, radiologic imaging (CT, bone scan), and clinical exams to monitor closely for progression.
  • The prostate cancer trials working group (PCWG) has also published additional recommendations.
Monitoring recommendations/guidelines by NCCN for metastatic disease1   Indicators of disease progression according to PCWG32
PSA measurement every 3-6 months based on clinical judgement

Increased risk for bone metastasis or death with a PSADT of <8 months
  Rising PSA levels
Frequency of imaging should be based on individual risk, age, PSADT, Gleason score, and overall health.

i.e. bone scans* every 8-12 weeks
PSADT <8 months, perform bone imaging more frequently
  New lesions
History and physical examination every 3-6 months   Pain

PSADT=PSA doubling time

*Bone scans are useful to monitor mCRPC to determine the clinical benefit of systematic therapy. However, new lesions comparing pre and post-treatment bone scans may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absence of pain progression at the site may indicate bone scan flare or an osteoblastic healing reaction.



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.


Our commitment to patients during COVID-19

Sanofi CareASSIST may be able to help address your patients’ financial assistance concerns during COVID-19. We understand that you and your patients may have concerns about paying for treatment. If your patients experience a change or loss in coverage, Sanofi CareASSIST may be able to help. You can call 1-833-WE+CARE (1-833-930-2273), and a Patient Access Specialist will review specific eligibility during this time. Please click here.

To learn about the Sanofi response to COVID-19, please click here.


MAT-US-2013902 07/20